The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
Expands manufacturing push & locks in major growth deals
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
NEJM study shows strong protection across strains
Hair care & quick commerce shine
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
Subscribe To Our Newsletter & Stay Updated
